Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of LY4302814 in Healthy Participants
Sponsor: Eli Lilly and Company
Summary
The main purpose of this study is to assess how well LY4302814 is tolerated and what side effects may occur in healthy participants. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. For each participant, the study will last about 6 months and will include at least one overnight stay in the clinical research unit (CRU) lasting up to approximately 9 days.
Official title: A Phase 1, Randomized, Placebo-Controlled, Investigator and Participant Blinded, Single Ascending Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4302814 in Healthy Participants
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
150
Start Date
2026-05-06
Completion Date
2027-08
Last Updated
2026-06-16
Healthy Volunteers
Yes
Conditions
Interventions
LY4302814
Administered SC
LY4302814
Administered IV
Placebo
Administered SC
Placebo
Administered IV
Locations (2)
Fortrea Clinical Research Unit
Daytona Beach, Florida, United States
Lilly Centre for Clinical Pharmacology
Singapore, Singapore